Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/12/2025

Acute Coronary Syndrome Management

Initial Assessment and Treatment

  • The European Society of Cardiology recommends that all patients with suspected acute coronary syndrome (ACS) receive aspirin 150-300 mg immediately and obtain a 12-lead ECG within 10 minutes of first medical contact, while simultaneously drawing high-sensitivity troponin with results available within 60 minutes 1, 2, 3, 4
  • For patients with STEMI, the European Society of Cardiology recommends activating the catheterization laboratory immediately for primary PCI within 120 minutes of presentation, or administering fibrinolytic therapy if PCI will be delayed beyond 120 minutes 1, 3
  • For patients with NSTE-ACS, the European Society of Cardiology recommends proceeding with risk stratification algorithm, as these patients show transient ST-depression, T-wave inversion, or non-diagnostic ECG changes 1, 2, 5

Antiplatelet and Anticoagulation Therapy

  • The European Society of Cardiology recommends aspirin 150-300 mg loading dose, then 75-100 mg daily indefinitely, and adding a P2Y12 inhibitor immediately, with ticagrelor 180 mg loading dose, then 90 mg twice daily preferred over clopidogrel for all NSTE-ACS patients regardless of management strategy 1, 3, 4
  • The European Society of Cardiology recommends fondaparinux 2.5 mg subcutaneously once daily as the anticoagulant with the best efficacy-safety profile, with alternative options including enoxaparin, unfractionated heparin, or bivalirudin based on institutional protocols 1, 3, 4, 6

Risk Stratification and Invasive Strategy

  • The European Society of Cardiology recommends proceeding directly to catheterization laboratory if any high-risk features are present, including hemodynamic instability, recurrent/ongoing chest pain, life-threatening arrhythmias, or mechanical complications 1, 2, 4, 5
  • For high-risk patients, the European Society of Cardiology recommends performing coronary angiography within 24 hours if any of the following are present: confirmed NSTEMI, dynamic ST-segment or T-wave changes, GRACE risk score >140, or transient ST-segment elevation 1, 2, 3, 4

Technical Considerations for Invasive Procedures

  • The European Society of Cardiology recommends radial artery access as mandatory over femoral access to reduce bleeding complications, and drug-eluting stents as preferred over bare-metal stents for all PCI regardless of clinical presentation or anticipated DAPT duration 1, 4
  • The European Society of Cardiology recommends emergency CABG if coronary anatomy is not amenable to PCI in high-risk or cardiogenic shock patients 1, 3, 5

Critical Monitoring and Laboratory Assessment

  • The European Society of Cardiology recommends high-sensitivity troponin at 0 and 1-2 hours to allow rapid rule-in/rule-out with ≥99% sensitivity, and results must be available within 60 minutes of blood draw 2, 3, 4, 6
  • The European Society of Cardiology recommends additional blood work on admission, including serum creatinine, hemoglobin, hematocrit, platelet count, blood glucose, and lipid profile, as well as INR if on warfarin 3, 4, 6

Special Populations Requiring Modified Approach

  • The European Society of Cardiology recommends applying same diagnostic and therapeutic strategies for patients with chronic kidney disease/ESRD, but with mandatory dose adjustment of all anticoagulants and antiplatelet agents based on creatinine clearance 1, 4
  • The European Society of Cardiology recommends using low- or iso-osmolar contrast at minimum volume during angiography, and chronically elevated baseline troponin requires assessment of dynamic changes rather than absolute values 1, 4

Secondary Prevention

  • The European Society of Cardiology recommends starting mandatory therapies before discharge, including high-intensity statin, beta-blocker, ACE inhibitor or ARB, and aspirin plus ticagrelor for 12 months, then aspirin monotherapy indefinitely 1, 3, 6